Healthy Volunteers Clinical Trial
Official title:
Psychophysical Correlates of Pain Reduction by Topical Analgesic Compounds
| Verified date | July 2, 2018 |
| Source | National Institutes of Health Clinical Center (CC) |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Background:
- Researchers are studying a topical (skin) cream that reduces pain. This is called an
analgesic cream. They want to try a new test to better measure how well it works. Heat will
be applied to the participants arms and they will judge the intensity of the temperatures.
Researchers will compare the pain reduction from this cream to other pain relief treatments.
Objective:
- To better measure the effects of a pain-relieving (analgesic) cream.
Eligibility:
- Healthy volunteers ages 18 50.
Design:
- There will be 2 study sessions.
- Session 1 will be about 1.5 hours.
- Participants will be screened with physical exam and urine drug test. They will
answer medical and psychological questions.
- Participants will have sensory testing.
- A moisturizer will be put on their arms. A heating device will be placed on their arms.
It gives heat pulses of about 2 seconds each. Some are warm and some are very hot.
Participants will say how strong each pulse is. They can move away if it gets painful.
- Then the pain-relieving cream will be put on one arm. The moisturizer will be put on the
other. Participants will get more pulses and rate them. They will also get pairs of
pulses and compare them.
- Some participants will return for session 2 for 1 hour. They will receive similar
sensory testing as in session 1.
| Status | Completed |
| Enrollment | 40 |
| Est. completion date | July 2, 2018 |
| Est. primary completion date | September 21, 2017 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years to 50 Years |
| Eligibility |
- INCLUSION CRITERIA: You may be eligible to participate in this research study if you are: 1. Between 18 and 50 years old. 2. Fluent in English. 3. Able to understand the procedures described in this document and give your written consent. EXCLUSION CRITERIA: You may not be eligible to participate in this research study if you: 1. Cannot complete the required procedures and tests in the study 2. Used recreational drugs within the past six months 3. Are in the third trimester of pregnancy 4. Have a major medical condition or major medical history event that could affect touch and pain 5. Have a medical condition that might affect touch and pain (e.g. Raynaud s Disease, peripheral neuropathy, or circulatory disorder) 6. Have chronic pain or a history or chronic pain 7. Have allergies to topical treatments 8. Have a dermatological condition such as scars or burns, or have had a tattoo on your forearms within the previous four weeks that might influence touch or pain 9. Had a recent or permanent injury of upper limbs or amputation or use a prosthetic limb 10. Have participated in related NIH protocols (we will determine this) 11. Used non-steroidal anti-inflammatory drugs (NSAIDS, e.g. aspirin, ibuprofen), acetaminophen, or sumatriptan within 3 days of testing (brand names include Advil, Tylenol, and Imitrex) 12. Used narcotics (e.g. opioids, oxycodone) or pseudo narcotics (e.g. tramadol, tapentadol) within one week of testing (brand names include Percocet and Ultram) 13. Use centrally acting medications like anticonvulsants (e.g. gabapentin, pregabalin), antidepressants (e.g. fluoxetine, duloxetine), antipsychotics (e.g. chlorpromazine, prochlorperazine), or anxiolytics (e.g. clonazepam, alprazolam) (Brand names include Neurontin, Lyrica, Prozac, Cymbalta, and Xanax) 14. Use tobacco daily or used tobacco within 24 hours of testing 15. Used topical pain-relieving creams in the testing area (e.g. methylsalicylate, capsaicin) within 24 hours of testing (Brand names include IcyHot and BenGay) 16. Cannot schedule two sessions within two weeks 17. Have consumed caffeine before 2 hours of testing |
| Country | Name | City | State |
|---|---|---|---|
| United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
| Lead Sponsor | Collaborator |
|---|---|
| National Center for Complementary and Integrative Health (NCCIH) |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Thermal sensory discrimination | One time point |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
| Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
| Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
| Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
| Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
| Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
| Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
| Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
| Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
| Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
| Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
| Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
| Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
| Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
| Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
| Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
| Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |